Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Rocket Pharmaceuticals (NASDAQ: RCKT), a late-stage biotechnology company focusing on genetic therapies for rare disorders, has announced its participation in two upcoming investor conferences. The company will be present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, at 2:35 PM ET, and the 2024 Cantor Fitzgerald Global Healthcare Conference on September 17, 2024, at 10:55 AM ET.

CEO Gaurav Shah, M.D., will engage in fireside chats at both events, and the management team will host investor meetings. Webcasts of the presentations will be accessible on the Investors section of Rocket Pharmaceuticals' website, providing an opportunity for stakeholders to stay informed about the company's progress and strategies in developing genetic therapies for rare disorders with high unmet needs.

CRANBURY, N.J.--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the Morgan Stanley 22^nd Annual Global Healthcare Conference and the 2024 Cantor Fitzgerald Global Healthcare Conference in New York. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat and management will host investor meetings at each conference. Participation details are as follows:

Morgan Stanley 22^nd Annual Global Healthcare Conference
Date: September 5, 2024
Time: 2:35 PM ET

2024 Cantor Fitzgerald Global Healthcare Conference
Date: September 17, 2024
Time: 10:55 AM ET

Webcasts of the presentations will be available here on the Investors section of the Company’s website.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Rocket’s innovative multi-platform approach allows us to design the optimal gene therapy for each indication, creating potentially transformative options that enable people living with devastating rare diseases to experience long and full lives.

Rocket’s lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia.

Rocket’s adeno-associated viral (AAV) vector-based cardiovascular portfolio includes a late-stage program for Danon Disease, a devastating heart failure condition resulting in thickening of the heart, an early-stage program in clinical trials for PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death, and a pre-clinical program targeting BAG3-associated dilated cardiomyopathy (DCM), a heart failure condition that causes enlarged ventricles.

For more information about Rocket, please visit www.rocketpharma.com and follow us on LinkedIn, YouTube, and X.

Rocket Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements concerning Rocket’s future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this release are forward-looking statements. You should not place reliance on these forward-looking statements, which often include words such as “could,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “will give,” “estimate,” “seek,” “will,” “may,” “suggest” or similar terms, variations of such terms or the negative of those terms. These forward-looking statements include, but are not limited to, statements concerning Rocket’s expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other diseases, the expected timing and data readouts of Rocket’s ongoing and planned clinical trials, the expected timing and outcome of Rocket’s regulatory interactions and planned submissions, including the timing and outcome of the FDA’s review of the additional CMC information that Rocket will provide in response to the FDA’s request, the safety, effectiveness and timing of pre-clinical studies and clinical trials, Rocket’s ability to establish key collaborations and vendor relationships for its product candidates, Rocket’s ability to develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates, Rocket’s ability to expand its pipeline to target additional indications that are compatible with its gene therapy technologies, Rocket’s ability to transition to a commercial stage pharmaceutical company, and Rocket’s expectation that its cash, cash equivalents and investments will be sufficient to funds its operations into 2026. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, unexpected expenditures, Rocket’s competitors’ activities, including decisions as to the timing of competing product launches, pricing and discounting, Rocket’s ability to develop, acquire and advance product candidates into, enroll a sufficient number of patients into, and successfully complete, clinical studies, the integration of new executive team members and the effectiveness of the newly configured corporate leadership team, Rocket’s ability to acquire additional businesses, form strategic alliances or create joint ventures and its ability to realize the benefit of such acquisitions, alliances or joint ventures, Rocket’s ability to obtain and enforce patents to protect its product candidates, and its ability to successfully defend against unforeseen third-party infringement claims, as well as those risks more fully discussed in the section entitled “Risk Factors” in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2023, filed February 27, 2024 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240827605338/en/

Media & Investors

Meg Dodge

mdodge@rocketpharma.com

Media

Kevin Giordano

media@rocketpharma.com

Investors

Brooks Rahmer

investors@rocketpharma.com

Source: Rocket Pharmaceuticals, Inc.

FAQ

When is Rocket Pharmaceuticals (RCKT) participating in the Morgan Stanley Healthcare Conference?

Rocket Pharmaceuticals (RCKT) is participating in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, at 2:35 PM ET.

What is the date and time for Rocket Pharmaceuticals' (RCKT) presentation at the Cantor Fitzgerald Global Healthcare Conference?

Rocket Pharmaceuticals (RCKT) is presenting at the 2024 Cantor Fitzgerald Global Healthcare Conference on September 17, 2024, at 10:55 AM ET.

Who will be representing Rocket Pharmaceuticals (RCKT) at the upcoming investor conferences?

Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals (RCKT), will participate in fireside chats at the upcoming investor conferences.

How can investors access Rocket Pharmaceuticals' (RCKT) presentations from the healthcare conferences?

Webcasts of Rocket Pharmaceuticals' (RCKT) presentations will be available on the Investors section of the company's website.

What type of therapies does Rocket Pharmaceuticals (RCKT) focus on developing?

Rocket Pharmaceuticals (RCKT) focuses on developing genetic therapies for rare disorders with high unmet needs.